The possible mediatory role of adipokines in the association between low carbohydrate diet and depressive symptoms among overweight and obese women.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
06
2020
accepted:
28
08
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
24
11
2021
Statut:
epublish
Résumé
Previous studies showed the possible association between obesity, dietary pattern, and depressive symptoms. Due to the lack of enough data to confirm the association of obesity and depression in the Middle East, here, we aimed to explore the possible mediatory role of adipokines Galectin-3, transforming growth factor-beta (TGF-β), and endothelial plasminogen activator inhibitor (PAI-1) in the association between low carbohydrate diet (LCD) and depressive symptoms. A total of 256 women aged 17-56 years old were grouped based on their LCD score. Depression anxiety stress scales-21 (DASS-21) self-administered questionnaire was used to evaluate the three negative emotional states of stress, depressive symptoms, and anxiety. Body composition and dietary intake were assessed. Enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of Galectin-3, TGF-β, and PAI-1. No significant difference was observed regarding Galectin-3, TGF-β, and PAI-1 levels between the groups with dissimilar adherence to LCD or the groups with different levels of depressive symptoms (P>0.05). However, there was a negative association between LCD score as a covariant and depressive symptoms as an independent variable (P = 0.02) and remarkably, a regression model linear analysis using Galectin-3, TGF-β, and PAI-1 as confounding variables indicated the mediatory role of these adipokines in this association (P>0.05). In other words, adipokines eliminated the significance of the relationship between adherence to LCD and depressive symptoms. It seems that higher adherence to LCD is probably associated with a lower prevalence of depressive symptoms in obese adults through the mediatory role of adipokines.
Sections du résumé
BACKGROUND
Previous studies showed the possible association between obesity, dietary pattern, and depressive symptoms. Due to the lack of enough data to confirm the association of obesity and depression in the Middle East, here, we aimed to explore the possible mediatory role of adipokines Galectin-3, transforming growth factor-beta (TGF-β), and endothelial plasminogen activator inhibitor (PAI-1) in the association between low carbohydrate diet (LCD) and depressive symptoms.
METHODS
A total of 256 women aged 17-56 years old were grouped based on their LCD score. Depression anxiety stress scales-21 (DASS-21) self-administered questionnaire was used to evaluate the three negative emotional states of stress, depressive symptoms, and anxiety. Body composition and dietary intake were assessed. Enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of Galectin-3, TGF-β, and PAI-1.
RESULTS
No significant difference was observed regarding Galectin-3, TGF-β, and PAI-1 levels between the groups with dissimilar adherence to LCD or the groups with different levels of depressive symptoms (P>0.05). However, there was a negative association between LCD score as a covariant and depressive symptoms as an independent variable (P = 0.02) and remarkably, a regression model linear analysis using Galectin-3, TGF-β, and PAI-1 as confounding variables indicated the mediatory role of these adipokines in this association (P>0.05). In other words, adipokines eliminated the significance of the relationship between adherence to LCD and depressive symptoms.
CONCLUSION
It seems that higher adherence to LCD is probably associated with a lower prevalence of depressive symptoms in obese adults through the mediatory role of adipokines.
Identifiants
pubmed: 34516574
doi: 10.1371/journal.pone.0257275
pii: PONE-D-20-17534
pmc: PMC8437289
doi:
Substances chimiques
Adipokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0257275Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
CMAJ. 2020 Aug 4;192(31):E875-E891
pubmed: 32753461
Transl Psychiatry. 2019 Apr 26;9(1):144
pubmed: 31028243
Nutr Metab Cardiovasc Dis. 2020 Apr 12;30(4):581-588
pubmed: 32008914
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
J Clin Med. 2020 Jul 23;9(8):
pubmed: 32717793
Public Health Nutr. 2019 Jun;22(8):1415-1424
pubmed: 30585572
Metab Syndr Relat Disord. 2012 Dec;10(6):437-42
pubmed: 22889406
Mediators Inflamm. 2019 Jun 3;2019:8373060
pubmed: 31281229
BMC Res Notes. 2020 Apr 14;13(1):212
pubmed: 32290863
Int J Qual Stud Health Well-being. 2018 Dec;13(1):1487762
pubmed: 29947301
J Nutr Health Aging. 2020;24(7):805-808
pubmed: 32744579
Metabolism. 2019 Mar;92:6-10
pubmed: 30253139
Front Cell Neurosci. 2018 Nov 20;12:439
pubmed: 30515083
Obesity (Silver Spring). 2017 Mar;25(3):500-501
pubmed: 28229549
Br J Pharmacol. 2018 May;175(10):1569-1579
pubmed: 29486050
Psychiatry Investig. 2020 Aug;17(8):715-724
pubmed: 32777922
J Postgrad Med. 2017 Jul-Sep;63(3):182-190
pubmed: 28695871
Dis Markers. 2018 Oct 10;2018:3406028
pubmed: 30405857
Life Sci. 2020 Oct 1;258:118124
pubmed: 32702443
Eur J Nutr. 2018 Jun;57(4):1301-1312
pubmed: 29541907
Sci Rep. 2020 Sep 2;10(1):14423
pubmed: 32879368
Pain. 1983 Sep;17(1):45-56
pubmed: 6226917
Exp Ther Med. 2021 Jan;21(1):90
pubmed: 33363601
Physiol Rep. 2017 Nov;5(21):
pubmed: 29122953
J Clin Med. 2020 Nov 24;9(12):
pubmed: 33255237
Nutrients. 2018 Feb 09;10(2):
pubmed: 29425182
Nutrients. 2019 Sep 30;11(10):
pubmed: 31574939
BMC Res Notes. 2020 Mar 30;13(1):189
pubmed: 32228677
Curr Diab Rep. 2018 Jul 30;18(9):69
pubmed: 30058013
Curr Opin Pharmacol. 2007 Dec;7(6):648-52
pubmed: 18032111
Sleep Breath. 2019 Dec;23(4):1107-1114
pubmed: 30721387
Nutrients. 2020 May 03;12(5):
pubmed: 32375291
Pharmacol Res. 2018 Apr;130:374-384
pubmed: 29438781
PLoS One. 2018 Jan 30;13(1):e0192159
pubmed: 29381773
Clin Nutr. 2018 Dec;37(6 Pt A):1871-1878
pubmed: 29258678
BMC Womens Health. 2021 Mar 1;21(1):87
pubmed: 33648476
J Affect Disord. 2021 Feb 15;281:384-389
pubmed: 33352408
Appetite. 2009 Feb;52(1):96-103
pubmed: 18804129
Curr Obes Rep. 2018 Jun;7(2):193-203
pubmed: 29663153
Mol Psychiatry. 2006 Oct;11(10):892-902
pubmed: 16880826
Arch Iran Med. 2014 Jun;17(6):417-22
pubmed: 24916527
J Health Popul Nutr. 2011 Feb;29(1):39-52
pubmed: 21528789
Endocr Connect. 2018 Jun;7(6):819-828
pubmed: 29760188
Dialogues Clin Neurosci. 2011;13(1):73-87
pubmed: 21485748
Psychoneuroendocrinology. 2018 Nov;97:20-27
pubmed: 30005278
Arch Physiol Biochem. 2019 Sep 4;:1-8
pubmed: 31482741
Arch Intern Med. 2009 Nov 9;169(20):1873-80
pubmed: 19901139
PLoS One. 2019 Mar 8;14(3):e0213573
pubmed: 30849107
Med Clin North Am. 2018 Jan;102(1):183-197
pubmed: 29156185
Appetite. 2016 Dec 1;107:253-259
pubmed: 27507131
Diabetol Metab Syndr. 2020 Apr 29;12:36
pubmed: 32368256
Sci Rep. 2020 Aug 31;10(1):14321
pubmed: 32868802
Behav Res Ther. 1997 Jan;35(1):79-89
pubmed: 9009048
J Obes. 2010;2010:
pubmed: 20798882
Diabetes Metab Syndr Obes. 2021 Feb 16;14:705-717
pubmed: 33623406